Combination therapy 'does not cut cardiovascular risk'
03 September 2009
Combination therapy with angiotensin II-receptor blockers (ARBs) and ACE inhibitors does not appear to reduce the risk of cardiovascular death among patients with heart failure compared with ACE inhibitor therapy alone, a Swiss study has found.
Combination therapy did not affect cardiovascular risk
Instead, the researchers found that combination therapy was associated with more adverse events such as worsening renal function and symptomatic hypertension.
For the study, a meta-analysis of eight trials involving 18,061 patients was carried out. All of the trials compared the combination of ARBs and ACE inhibitors with ACE inhibitor therapy in patients with heart failure.
No difference in overall mortality rates was seen between patients on combination therapy and ACE inhibitor therapy.
The researchers, led by Dr Alain Nordmann, from the University Hospital Basel, concluded that ‘combined therapy with ARBs and ACE inhibitors may be reserved for patients who remain symptomatic on therapy with ACE inhibitors under strict monitoring'.
Research was presented at this week's European Society of Cardiology conference in Barcelona, Spain.
* Read two pages of news from this conference in this week's GP dated 4 September.
Additional Information
Latest jobs Jobs web feed
- 2X Part Time Salaried GPs Deerness Park Medical Centre Competitive, Sunderland Tyne & Wear
- Full time GP partner - Isle of Man Laxey and Village Walk Health Centres Competitive, Isle of Man
- A&E Specialty Doctors Hays Healthcare £36000.00 - £68000.00 per annum, London
- GP Locum in Dorset - Short Term Locum Fresh Medical Recruitment £70 per hour, Dorset
- GP Locum in North London - Weekday Shifts Fresh Medical Recruitment £70 per hour, London
- Consultant A&E Doctors Hays Healthcare £74000.00 - £100000.00 per annum, London
Most read
Most commented
MIMS Drug Search
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
